Journal ArticleOPEN ACCESS

Regulators approve the first cancer-killing virus

  • Mullard A
Nature Reviews Drug Discovery (2015) 14(12) 811-811
DOI: 10.1038/nrd4805
N/ACitations
Citations of this article
9Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Regulators in the United States and Europe have approved Amgen's talimogene laherparepvec, a genetically modified live oncolytic herpesvirus therapy that replicates inside cancer cells and causes them to rupture and die.

Cite

CITATION STYLE

APA

Mullard, A. (2015). Regulators approve the first cancer-killing virus. Nature Reviews Drug Discovery, 14(12), 811–811. https://doi.org/10.1038/nrd4805

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free